Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Obinutuzumab, Glofitamab and Lenalidomide for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma Previously Treated with a BTK Inhibitor

Trial Status: active

This phase I clinical trial studies how well obinutuzumab given before glofitamab and lenalidomide works in treating patients with mantle cell lymphome (MCL) that has come back after a period of improvement (relapsed) or that has not responded to previous treatment (refractory). Glofitamab and obinutuzumab are monoclonal antibodies that may interfere with the ability of cancer cells to grow and spread. Obinutuzumab may also reduce the risk of immune-related conditions from treatment. Lenalidomide is a drug that alters the immune system, and it may also interfere with the development of tiny blood vessels that help support tumor growth, reducing or preventing the growth of cancer cells. Giving obinutuzumab before glofitamab may decrease the side effects of glofitamab and glofitamab and lenalidomide may work better for the treatment of relapsed or refractory MCL.